Skip to main content
Erschienen in: Cancer Causes & Control 11/2017

08.11.2017 | Original paper

The prostate cancer screening clinic in the Bahamas: a model for low- and middle-income countries

verfasst von: Robin Roberts, Corydon Mitchell, Ana Lourdes Tancawan, Mandi Pedican, Glenn Wayne Jones

Erschienen in: Cancer Causes & Control | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Grand Bahama (pop. 51,000) is an island within the Bahamas archipelago. A local chapter of International Us TOO Prostate Cancer Support Group (UTGB) has led an annual community-based prostate cancer screening clinic in Grand Bahama each September since 2009. Features of this initiative, characteristics of attendees, and a description of found cancers were summarized to determine the clinic’s value and to guide improvements.

Method

We analyzed the established clinic from 2012 to 2015, wherein UTGB attracted corporate funding, volunteers managed clinics, and health professionals provided healthcare services. An explicit algorithm was used to sort clients by age, comorbidities, and findings from digital rectal examinations, and prostate-specific antigen (PSA) values, to determine which clients would undergo secondary assessment and prostate biopsy.

Results

Overall, 1,844 males were registered (mean age 57.6 years), and only 149 men attended on more than one occasion for a total of 1,993 clinic visit. The urologist reviewed 315 men in secondary follow-up, for elevated PSA and/or an abnormal digital rectal examination. Of these, 45 men fulfilled criteria for trans-rectal ultrasound biopsy, and there were 40 found cases of prostate cancer, for a positive-predictive value of 89%. By D’Amico risk-stratification, these 40 cases were low (10%), intermediate (40%), and high risk (50%). The urologist counseled all 40 cases and facilitated access to standard care.

Conclusion

This study suggests that low-resource countries can advance cost-effective screening clinics, apply policy guidelines, and provide services within acceptable standards of care. It is the expectation, with a sustained effort and community participation over the ensuing years, that earlier disease presentation will occur and, consequently, a concomitant decrease in the disease-specific mortality.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Roberts RA et al. (2009) 2nd American Association of Cancer Research Cancer Conference: The Science of Cancer Health Disparities in Racial /Ethnic Minorities and the Medically Underserved Conference. Arizona: Prostate cancer burden in the Bahamas: real men die from prostate cancer. Abstract # 218 Roberts RA et al. (2009) 2nd American Association of Cancer Research Cancer Conference: The Science of Cancer Health Disparities in Racial /Ethnic Minorities and the Medically Underserved Conference. Arizona: Prostate cancer burden in the Bahamas: real men die from prostate cancer. Abstract # 218
4.
Zurück zum Zitat Razzaghi H et al (2017) Leading causes of cancer mortality—Caribbean region, 2003–2013. Morb Mortal Wkly Rep 65:1395–1400CrossRef Razzaghi H et al (2017) Leading causes of cancer mortality—Caribbean region, 2003–2013. Morb Mortal Wkly Rep 65:1395–1400CrossRef
5.
Zurück zum Zitat Odedina FT et al (2009) Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 4(Suppl 10):S2CrossRefPubMedPubMedCentral Odedina FT et al (2009) Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 4(Suppl 10):S2CrossRefPubMedPubMedCentral
6.
8.
Zurück zum Zitat Heidenreich A, Bastian PJ, Bellmunt J, Bolla M (2013) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol. doi:10.1016/j.eururo.2013.09.046 Heidenreich A, Bastian PJ, Bellmunt J, Bolla M (2013) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol. doi:10.​1016/​j.​eururo.​2013.​09.​046
9.
Zurück zum Zitat Pasick R, Hiatt R, Paskett E (2004) Lessons Learned from Community-Based Cancer Screening Intervention Research. Cancer 101(Suppl 5):1146–1164CrossRefPubMed Pasick R, Hiatt R, Paskett E (2004) Lessons Learned from Community-Based Cancer Screening Intervention Research. Cancer 101(Suppl 5):1146–1164CrossRefPubMed
10.
Zurück zum Zitat Government of the Bahamas Department of Statistics Population and Census. bahamas.gov.org. Accessed 4 Jan 2017 Government of the Bahamas Department of Statistics Population and Census. bahamas.gov.org. Accessed 4 Jan 2017
13.
Zurück zum Zitat Ahmad S, Manecksha RP, Cullen IM et al (2011) Estimation of clinically significant prostate volumes by digital rectal examination: a comparative prospective study. Can J Urol 18(6):6025–6030PubMed Ahmad S, Manecksha RP, Cullen IM et al (2011) Estimation of clinically significant prostate volumes by digital rectal examination: a comparative prospective study. Can J Urol 18(6):6025–6030PubMed
14.
Zurück zum Zitat Cheng WC, Ng FC, Chan KC et al (2004) Interobserver variation of prostatic volume estimation with digital rectal examination by urological staffs with different experiences. Intern Braz J Urology 30(6):466–471CrossRef Cheng WC, Ng FC, Chan KC et al (2004) Interobserver variation of prostatic volume estimation with digital rectal examination by urological staffs with different experiences. Intern Braz J Urology 30(6):466–471CrossRef
15.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation Therapy, or interstitial radiation therapy for localized prostate cancer. JAMA 280:969–74CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation Therapy, or interstitial radiation therapy for localized prostate cancer. JAMA 280:969–74CrossRefPubMed
16.
Zurück zum Zitat Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67(2):316–320CrossRefPubMed Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67(2):316–320CrossRefPubMed
17.
Zurück zum Zitat Preston MA, Batista JL, Wilson KM et al (2016) Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J. Clin Oncol 34(23):2705–2711CrossRefPubMedPubMedCentral Preston MA, Batista JL, Wilson KM et al (2016) Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J. Clin Oncol 34(23):2705–2711CrossRefPubMedPubMedCentral
19.
20.
Zurück zum Zitat Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, SPCG-4 Investigators et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708–1717CrossRefPubMed Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, SPCG-4 Investigators et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708–1717CrossRefPubMed
21.
Zurück zum Zitat Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725–732CrossRefPubMedPubMedCentral Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725–732CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Moyer VA (2012) U.S. Preventive services task force. Screening for prostate cancer. U.S. preventive services task force recommendation statement. Ann Intern Med 157:120–134CrossRefPubMed Moyer VA (2012) U.S. Preventive services task force. Screening for prostate cancer. U.S. preventive services task force recommendation statement. Ann Intern Med 157:120–134CrossRefPubMed
23.
Zurück zum Zitat Klotz L et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272CrossRefPubMed Klotz L et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272CrossRefPubMed
24.
Zurück zum Zitat Health Information and Research Unit, Ministry of Health Nassau, Bahamas Health Information and Research Unit, Ministry of Health Nassau, Bahamas
26.
Zurück zum Zitat Sackett DL, Haynes RB, Tugwell P (1985) Clinical epidemiology: a basic science for clinical medicine. Little, Brown and Company, Toronto, pp 106–107 Sackett DL, Haynes RB, Tugwell P (1985) Clinical epidemiology: a basic science for clinical medicine. Little, Brown and Company, Toronto, pp 106–107
28.
Zurück zum Zitat Morash C, Tey R, Aqbassi C, Klotz L, McGowan T, Srigley J, Evans A (2015) Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 9:171–178CrossRefPubMedPubMedCentral Morash C, Tey R, Aqbassi C, Klotz L, McGowan T, Srigley J, Evans A (2015) Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 9:171–178CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Filella X, Foj L (2016) Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. 17(11):1784. doi:10.3390/ijms17111784 Filella X, Foj L (2016) Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. 17(11):1784. doi:10.​3390/​ijms17111784
34.
Zurück zum Zitat Sullivan T, Sullivan R, Ginsburg OM (2015) Chap. 12, Screening for cancer: considerations for low- and middle-income countries. In: Gelband H, Sankaranarayanan R et al (eds) Cancer: disease control priorities, vol 3, 3rd. World Bank. International Bank for Reconstruction and Development, Washington DC Sullivan T, Sullivan R, Ginsburg OM (2015) Chap. 12, Screening for cancer: considerations for low- and middle-income countries. In: Gelband H, Sankaranarayanan R et al (eds) Cancer: disease control priorities, vol 3, 3rd. World Bank. International Bank for Reconstruction and Development, Washington DC
Metadaten
Titel
The prostate cancer screening clinic in the Bahamas: a model for low- and middle-income countries
verfasst von
Robin Roberts
Corydon Mitchell
Ana Lourdes Tancawan
Mandi Pedican
Glenn Wayne Jones
Publikationsdatum
08.11.2017
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 11/2017
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0972-1

Weitere Artikel der Ausgabe 11/2017

Cancer Causes & Control 11/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.